Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma

BACKGROUND: Cytotoxic chemotherapy (CC) is currently used in metastatic melanoma after patients have developed resistance to immune checkpoint inhibitors (ICI) and/or Mitogen‐Activated Protein Kinase inhibitors (MAPKi). We sought to evaluate if a previous treatment by ICI or MAPKi influences clinica...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Med
Egile Nagusiak: Mangin, Marie‐Alix, Boespflug, Amélie, Maucort Boulch, Delphine, Vacheron, Charles‐Hervé, Carpentier, Isabelle, Thomas, Luc, Dalle, Stéphane
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2021
Gaiak:
Clinical Cancer Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8124115/
https://ncbi.nlm.nih.gov/pubmed/33932099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3760
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak